Chembio Diagnostics to Participate in Upcoming Investor Conferences
Chembio Diagnostics, a leader in point-of-care diagnostics, announced participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chembio Diagnostics, a leader in point-of-care diagnostics, announced participation in two investor conferences. The management team will attend the virtual 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020, followed by the Benchmark Healthcare House Call Virtual Conference on June 16, 2020. Notably, these events do not include webcasts. Chembio specializes in diagnosing infectious diseases, leveraging its patented DPP technology for rapid testing. Their products cater to diverse markets including hospitals, clinics, and consumers.
Details
News Market Reaction – CEMI
The recorded move for CEMI in the trading session of this news was -4.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAUPPAUGE, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the company plans to participate in two upcoming investor conferences.
Management is scheduled to participate in the virtual 17th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 27, 2020.
Management is also scheduled to participate in the Benchmark Healthcare House Call Virtual Conference on Tuesday, June 16, 2020. Due to the format of these events no webcasts are available.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.
Contact:
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.